Commentary by Marilena S. Antonopoulos Pharm.D, Pharmacology Section Editor
Until recently, drugs safety alerts (aka “Dear Doctor letters”) were sent out to physicians through traditional U.S. mail, a slow and error-prone process. These alerts can be …
Commentary by Marilena S. Antonopoulos, PharmD, Pharmacology Editor
On July 8th, the FDA notified the manufacturers of fluoroquinolone antimicrobial drugs that a Boxed Warning in the product labeling and a Medication Guide for patients …
Commentary by Melissa Freeman, PGY-2
As summertime is just around the corner, many begin to evaluate whether their bodies are ready to expose what has been hidden under those bulky winter clothes. Between busy lives …
Commentary by David Hatcher, MSIII (reviewed by Neil Shapiro, MD Editor-In-Chief, Clinical Correlations)
C.M. is a 68 year-old retired Caucasian male with a past medical history significant for coronary artery disease, hyperlipidemia, HTN, …
Future Medicine is a new section of Clinical Correlations devoted to hot areas of research and development in various fields of medicine. In tihis series, we will highlight treatments in their infancy, from basic research opening up …
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our students in …
Is there evidence to support the use of Lantus® (human insulin analog glargine) administered Q12h in Type 1 Diabetes?
Commentary by Kathy Lee, Pharmacy Resident
The goal of diabetes management is to reduce the risk …
Commentary by Robert Leonard PharmD, Pharmacy Resident New York Harbor Healthcare System
On November 20, 2007 the FDA announced mounting evidence linking varenicline (Chantix®) therapy for smoking cessation with suicidal ideation and erratic and aggressive behavior. …